243 related articles for article (PubMed ID: 21068204)
1. Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study.
Kotlyar M; Hertsgaard LA; Lindgren BR; Jensen JA; Carmella SG; Stepanov I; Murphy SE; Hecht SS; Hatsukami DK
Cancer Epidemiol Biomarkers Prev; 2011 Jan; 20(1):91-100. PubMed ID: 21068204
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products.
Hatsukami DK; Lemmonds C; Zhang Y; Murphy SE; Le C; Carmella SG; Hecht SS
J Natl Cancer Inst; 2004 Jun; 96(11):844-52. PubMed ID: 15173268
[TBL] [Abstract][Full Text] [Related]
3. Randomised clinical trial of snus versus medicinal nicotine among smokers interested in product switching.
Hatsukami DK; Severson H; Anderson A; Vogel RI; Jensen J; Broadbent B; Murphy SE; Carmella S; Hecht SS
Tob Control; 2016 May; 25(3):267-74. PubMed ID: 25991608
[TBL] [Abstract][Full Text] [Related]
4. Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology.
Gray JN; Breland AB; Weaver M; Eissenberg T
Nicotine Tob Res; 2008 Sep; 10(9):1441-8. PubMed ID: 19023835
[TBL] [Abstract][Full Text] [Related]
5. Oral tobacco products: preference and effects among smokers.
Hatsukami DK; Jensen J; Anderson A; Broadbent B; Allen S; Zhang Y; Severson H
Drug Alcohol Depend; 2011 Nov; 118(2-3):230-6. PubMed ID: 21515003
[TBL] [Abstract][Full Text] [Related]
6. Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine.
Mendoza-Baumgart MI; Tulunay OE; Hecht SS; Zhang Y; Murphy S; Le C; Jensen J; Hatsukami DK
Nicotine Tob Res; 2007 Dec; 9(12):1309-23. PubMed ID: 18058349
[TBL] [Abstract][Full Text] [Related]
7. A two-site, two-arm, 34-week, double-blind, parallel-group, randomized controlled trial of reduced nicotine cigarettes in smokers with mood and/or anxiety disorders: trial design and protocol.
Allen SI; Foulds J; Pachas GN; Veldheer S; Cather C; Azzouz N; Hrabovsky S; Hameed A; Yingst J; Hammett E; Modesto J; Krebs NM; Zhu J; Liao J; Muscat JE; Richie J; Evins AE
BMC Public Health; 2017 Jan; 17(1):100. PubMed ID: 28103841
[TBL] [Abstract][Full Text] [Related]
8. Randomized Trial to Compare Smoking Cessation Rates of Snus, With and Without Smokeless Tobacco Health-Related Information, and a Nicotine Lozenge.
Nelson PR; Chen P; Battista DR; Pillitteri JL; Shiffman S
Nicotine Tob Res; 2019 Jan; 21(1):88-94. PubMed ID: 29373698
[TBL] [Abstract][Full Text] [Related]
9. Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers.
Hecht SS; Carmella SG; Murphy SE; Riley WT; Le C; Luo X; Mooney M; Hatsukami DK
Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1567-72. PubMed ID: 17684130
[TBL] [Abstract][Full Text] [Related]
10. Evaluating oral noncombustible potential-reduced exposure products for smokers.
Blank MD; Eissenberg T
Nicotine Tob Res; 2010 Apr; 12(4):336-43. PubMed ID: 20159791
[TBL] [Abstract][Full Text] [Related]
11. [Harm reduction strategy in tobacco control].
Gorini G
Epidemiol Prev; 2011; 35(3-4 Suppl 1):19-32. PubMed ID: 21926451
[TBL] [Abstract][Full Text] [Related]
12. Randomized crossover trial of the acceptability of snus, nicotine gum, and Zonnic therapy for smoking reduction in heavy smokers.
Caldwell B; Burgess C; Crane J
Nicotine Tob Res; 2010 Feb; 12(2):179-83. PubMed ID: 20064899
[TBL] [Abstract][Full Text] [Related]
13. Increased pouch sizes and resulting changes in the amounts of nicotine and tobacco-specific N-nitrosamines in single pouches of Camel Snus and Marlboro Snus.
Stepanov I; Jensen J; Biener L; Bliss RL; Hecht SS; Hatsukami DK
Nicotine Tob Res; 2012 Oct; 14(10):1241-5. PubMed ID: 22259150
[TBL] [Abstract][Full Text] [Related]
14. Clinical laboratory evaluation of potential reduced exposure products for smokers.
Breland AB; Kleykamp BA; Eissenberg T
Nicotine Tob Res; 2006 Dec; 8(6):727-38. PubMed ID: 17132520
[TBL] [Abstract][Full Text] [Related]
15. Evidence for endogenous formation of N'-nitrosonornicotine in some long-term nicotine patch users.
Stepanov I; Carmella SG; Han S; Pinto A; Strasser AA; Lerman C; Hecht SS
Nicotine Tob Res; 2009 Jan; 11(1):99-105. PubMed ID: 19246447
[TBL] [Abstract][Full Text] [Related]
16. A pilot randomized study of smokeless tobacco use among smokers not interested in quitting: changes in smoking behavior and readiness to quit.
Carpenter MJ; Gray KM
Nicotine Tob Res; 2010 Feb; 12(2):136-43. PubMed ID: 20053788
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers.
Cobb CO; Weaver MF; Eissenberg T
Tob Control; 2010 Oct; 19(5):367-73. PubMed ID: 19346218
[TBL] [Abstract][Full Text] [Related]
18. Brief, instructional smokeless tobacco use among cigarette smokers who do not intend to quit: a pilot randomized clinical trial.
Burris JL; Carpenter MJ; Wahlquist AE; Cummings KM; Gray KM
Nicotine Tob Res; 2014 Apr; 16(4):397-405. PubMed ID: 24130144
[TBL] [Abstract][Full Text] [Related]
19. Monitoring tobacco-specific N-nitrosamines and nicotine in novel Marlboro and Camel smokeless tobacco products: findings from Round 1 of the New Product Watch.
Stepanov I; Biener L; Knezevich A; Nyman AL; Bliss R; Jensen J; Hecht SS; Hatsukami DK
Nicotine Tob Res; 2012 Mar; 14(3):274-81. PubMed ID: 22039075
[TBL] [Abstract][Full Text] [Related]
20. Have combustible cigarettes met their match? The nicotine delivery profiles and harmful constituent exposures of second-generation and third-generation electronic cigarette users.
Wagener TL; Floyd EL; Stepanov I; Driskill LM; Frank SG; Meier E; Leavens EL; Tackett AP; Molina N; Queimado L
Tob Control; 2017 Mar; 26(e1):e23-e28. PubMed ID: 27729564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
